
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is experiencing strong growth in its molecular clinical test volume and revenue, primarily due to the success of its NeXT Personal MRD test. Continued investments in sales and expansion in coverage for IO monitoring indication are expected to contribute to significant revenue growth in the future. Additionally, the company's focus on precision oncology and strong IP strategy make it an attractive partner for collaborations with industry leaders.
Bears say
Personalis is currently showing signs of growth in its clinical test volume and expanding its customer base, however, the company is heavily reliant on a small number of pharmaceutical partnerships for revenue and lacks diversification in its product offerings. Additionally, while the company recently obtained Medicare coverage for one of its tests, it still holds a negative cash flow position and is subject to substantial cash raises and ATM facilities to sustain operations. Overall, the company's current reliance on a small number of partnerships and its negative cash flow position make it a risky investment.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares